Concepts (302)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Low Back Pain | 12 | 2020 | 44 | 3.020 |
Why?
|
| Analgesics, Opioid | 14 | 2022 | 247 | 1.890 |
Why?
|
| Pain, Postoperative | 10 | 2019 | 175 | 1.840 |
Why?
|
| Autonomic Nerve Block | 3 | 2015 | 9 | 1.490 |
Why?
|
| Pain Measurement | 18 | 2020 | 365 | 1.250 |
Why?
|
| Analgesics | 9 | 2018 | 126 | 1.110 |
Why?
|
| Perioperative Care | 3 | 2019 | 58 | 1.080 |
Why?
|
| Sacroiliac Joint | 3 | 2014 | 13 | 0.990 |
Why?
|
| Midazolam | 2 | 2014 | 11 | 0.970 |
Why?
|
| Diagnostic Techniques and Procedures | 2 | 2014 | 7 | 0.970 |
Why?
|
| Conscious Sedation | 2 | 2014 | 24 | 0.970 |
Why?
|
| Anesthetics, Intravenous | 2 | 2014 | 17 | 0.970 |
Why?
|
| Fentanyl | 2 | 2014 | 33 | 0.960 |
Why?
|
| Complex Regional Pain Syndromes | 2 | 2014 | 19 | 0.960 |
Why?
|
| Primary Health Care | 6 | 2022 | 183 | 0.930 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 223 | 0.920 |
Why?
|
| Obesity | 5 | 2014 | 1081 | 0.900 |
Why?
|
| Pain | 7 | 2012 | 285 | 0.890 |
Why?
|
| Humans | 58 | 2023 | 29552 | 0.860 |
Why?
|
| gamma-Aminobutyric Acid | 4 | 2008 | 74 | 0.850 |
Why?
|
| Osteoarthritis, Knee | 1 | 2023 | 81 | 0.840 |
Why?
|
| Electronic Health Records | 3 | 2019 | 121 | 0.770 |
Why?
|
| Opioid-Related Disorders | 6 | 2019 | 54 | 0.760 |
Why?
|
| Fear | 3 | 2014 | 44 | 0.680 |
Why?
|
| Buprenorphine | 1 | 2019 | 18 | 0.670 |
Why?
|
| Treatment Outcome | 15 | 2023 | 3128 | 0.660 |
Why?
|
| Zygapophyseal Joint | 2 | 2007 | 3 | 0.610 |
Why?
|
| Male | 37 | 2020 | 18012 | 0.580 |
Why?
|
| Resistance Training | 2 | 2014 | 73 | 0.580 |
Why?
|
| Anesthetics, Local | 3 | 2015 | 77 | 0.570 |
Why?
|
| Neuralgia | 2 | 2015 | 48 | 0.560 |
Why?
|
| Cyclohexanecarboxylic Acids | 3 | 2006 | 20 | 0.560 |
Why?
|
| Amines | 3 | 2006 | 22 | 0.560 |
Why?
|
| Denervation | 4 | 2008 | 13 | 0.540 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 376 | 0.540 |
Why?
|
| Stellate Ganglion | 1 | 2015 | 1 | 0.520 |
Why?
|
| Ventricular Fibrillation | 1 | 2015 | 4 | 0.510 |
Why?
|
| Medulla Oblongata | 5 | 2007 | 53 | 0.510 |
Why?
|
| Disability Evaluation | 3 | 2014 | 215 | 0.500 |
Why?
|
| Phantom Limb | 1 | 2014 | 4 | 0.490 |
Why?
|
| Receptors, Opioid, mu | 4 | 2007 | 51 | 0.490 |
Why?
|
| Middle Aged | 21 | 2019 | 10936 | 0.480 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 328 | 0.470 |
Why?
|
| Receptors, Opioid, delta | 5 | 2007 | 17 | 0.470 |
Why?
|
| Schools, Medical | 1 | 2014 | 42 | 0.460 |
Why?
|
| Exercise Therapy | 2 | 2014 | 237 | 0.450 |
Why?
|
| Faculty, Medical | 1 | 2014 | 69 | 0.440 |
Why?
|
| Anesthesiology | 1 | 2014 | 49 | 0.440 |
Why?
|
| Diabetic Neuropathies | 2 | 2013 | 23 | 0.440 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 145 | 0.410 |
Why?
|
| Female | 26 | 2020 | 18379 | 0.410 |
Why?
|
| Spinal Cord | 4 | 2004 | 139 | 0.410 |
Why?
|
| Nociceptors | 6 | 2004 | 41 | 0.410 |
Why?
|
| Health Behavior | 1 | 2013 | 217 | 0.410 |
Why?
|
| Osteoarthritis | 1 | 2012 | 74 | 0.390 |
Why?
|
| Postoperative Care | 3 | 2019 | 73 | 0.390 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2022 | 20 | 0.380 |
Why?
|
| Adult | 14 | 2020 | 8528 | 0.370 |
Why?
|
| Walking | 4 | 2014 | 185 | 0.350 |
Why?
|
| Anemia, Sickle Cell | 2 | 2020 | 40 | 0.350 |
Why?
|
| Catheter Ablation | 2 | 2008 | 62 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2017 | 471 | 0.330 |
Why?
|
| Societies, Medical | 3 | 2018 | 150 | 0.330 |
Why?
|
| Aged | 14 | 2018 | 9590 | 0.330 |
Why?
|
| Pain Threshold | 2 | 2008 | 95 | 0.320 |
Why?
|
| Ketamine | 2 | 2018 | 20 | 0.320 |
Why?
|
| Inflammation | 4 | 2007 | 511 | 0.310 |
Why?
|
| Hyperalgesia | 4 | 2007 | 88 | 0.310 |
Why?
|
| Patient Selection | 2 | 2022 | 257 | 0.310 |
Why?
|
| Spinal Diseases | 1 | 2007 | 17 | 0.310 |
Why?
|
| Risk Factors | 9 | 2019 | 3600 | 0.300 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 3 | 2007 | 18 | 0.300 |
Why?
|
| Cervical Vertebrae | 1 | 2007 | 42 | 0.300 |
Why?
|
| United States | 7 | 2020 | 3692 | 0.290 |
Why?
|
| Oligopeptides | 4 | 2007 | 51 | 0.280 |
Why?
|
| Orthopedic Procedures | 1 | 2007 | 93 | 0.280 |
Why?
|
| Ganglia, Spinal | 2 | 2006 | 63 | 0.280 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 71 | 0.280 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 104 | 0.270 |
Why?
|
| Analgesia | 2 | 2016 | 33 | 0.270 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 3764 | 0.270 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2007 | 748 | 0.250 |
Why?
|
| Physical Endurance | 3 | 2013 | 31 | 0.250 |
Why?
|
| Nerve Block | 3 | 2012 | 48 | 0.240 |
Why?
|
| Gait | 3 | 2014 | 120 | 0.240 |
Why?
|
| Radiosurgery | 1 | 2007 | 325 | 0.240 |
Why?
|
| Enkephalins | 2 | 2001 | 9 | 0.240 |
Why?
|
| Postural Balance | 1 | 2016 | 163 | 0.240 |
Why?
|
| Brain | 3 | 2019 | 933 | 0.230 |
Why?
|
| Pesticides | 1 | 2016 | 188 | 0.230 |
Why?
|
| Occupational Exposure | 1 | 2016 | 223 | 0.220 |
Why?
|
| Efferent Pathways | 1 | 2003 | 8 | 0.220 |
Why?
|
| Rats | 9 | 2007 | 1609 | 0.220 |
Why?
|
| Naproxen | 1 | 2002 | 8 | 0.220 |
Why?
|
| Algorithms | 2 | 2017 | 468 | 0.220 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 234 | 0.220 |
Why?
|
| Acetates | 1 | 2002 | 15 | 0.220 |
Why?
|
| Injections, Spinal | 3 | 2016 | 124 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 280 | 0.220 |
Why?
|
| Research Design | 2 | 2017 | 289 | 0.220 |
Why?
|
| Receptors, Opioid | 1 | 2003 | 38 | 0.210 |
Why?
|
| Neurons | 2 | 2003 | 395 | 0.210 |
Why?
|
| Consensus | 5 | 2019 | 70 | 0.210 |
Why?
|
| Muscle Strength | 2 | 2013 | 145 | 0.210 |
Why?
|
| Knee Joint | 1 | 2023 | 129 | 0.200 |
Why?
|
| Anesthesia, Conduction | 2 | 2018 | 29 | 0.200 |
Why?
|
| Hematology | 1 | 2020 | 5 | 0.190 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 796 | 0.190 |
Why?
|
| Animals | 12 | 2010 | 7339 | 0.180 |
Why?
|
| Body Mass Index | 3 | 2013 | 876 | 0.180 |
Why?
|
| Lower Extremity | 1 | 2020 | 97 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 903 | 0.170 |
Why?
|
| User-Computer Interface | 1 | 2019 | 34 | 0.170 |
Why?
|
| Periaqueductal Gray | 1 | 2019 | 2 | 0.170 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 16 | 0.150 |
Why?
|
| Classification | 1 | 2017 | 1 | 0.150 |
Why?
|
| Microinjections | 4 | 2001 | 33 | 0.150 |
Why?
|
| Analgesia, Epidural | 2 | 2010 | 50 | 0.150 |
Why?
|
| Medical History Taking | 1 | 2017 | 32 | 0.150 |
Why?
|
| Medical Informatics | 1 | 2016 | 18 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2016 | 129 | 0.140 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 65 | 0.140 |
Why?
|
| Lumbar Vertebrae | 2 | 2007 | 99 | 0.140 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 95 | 0.140 |
Why?
|
| Placebos | 1 | 2015 | 61 | 0.130 |
Why?
|
| Organizational Case Studies | 1 | 2015 | 12 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 62 | 0.130 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 209 | 0.130 |
Why?
|
| Neurosurgical Procedures | 1 | 2016 | 98 | 0.130 |
Why?
|
| Young Adult | 3 | 2019 | 2431 | 0.130 |
Why?
|
| Electric Countershock | 1 | 2015 | 10 | 0.130 |
Why?
|
| Sympathectomy | 1 | 2015 | 19 | 0.130 |
Why?
|
| Volleyball | 1 | 2015 | 1 | 0.130 |
Why?
|
| Terminology as Topic | 3 | 2019 | 63 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2015 | 3144 | 0.130 |
Why?
|
| Family Practice | 1 | 2015 | 49 | 0.130 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2008 | 40 | 0.130 |
Why?
|
| Drug Synergism | 4 | 2007 | 69 | 0.130 |
Why?
|
| Soccer | 1 | 2015 | 19 | 0.130 |
Why?
|
| Qualitative Research | 3 | 2020 | 143 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 247 | 0.120 |
Why?
|
| Overweight | 2 | 2013 | 261 | 0.120 |
Why?
|
| Spinal Nerves | 1 | 2015 | 65 | 0.120 |
Why?
|
| Brain Concussion | 1 | 2015 | 61 | 0.120 |
Why?
|
| Injections, Intra-Articular | 1 | 2014 | 13 | 0.120 |
Why?
|
| False Positive Reactions | 1 | 2014 | 25 | 0.120 |
Why?
|
| Efficiency | 1 | 2014 | 16 | 0.120 |
Why?
|
| Joints | 1 | 2013 | 9 | 0.120 |
Why?
|
| Baseball | 1 | 2015 | 39 | 0.120 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2013 | 5 | 0.120 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2013 | 17 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 156 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 253 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2013 | 64 | 0.110 |
Why?
|
| Health Policy | 1 | 2014 | 80 | 0.110 |
Why?
|
| Affect | 1 | 2013 | 64 | 0.110 |
Why?
|
| Phobic Disorders | 1 | 2013 | 8 | 0.110 |
Why?
|
| Time Factors | 5 | 2019 | 2014 | 0.110 |
Why?
|
| Chronic Disease | 3 | 2013 | 372 | 0.110 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2013 | 46 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2014 | 178 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2013 | 124 | 0.110 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 126 | 0.110 |
Why?
|
| Celiac Plexus | 1 | 2012 | 3 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2019 | 1329 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2014 | 333 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 525 | 0.100 |
Why?
|
| Incidence | 3 | 2019 | 1127 | 0.100 |
Why?
|
| Mobility Limitation | 1 | 2013 | 197 | 0.100 |
Why?
|
| Adolescent | 4 | 2019 | 3284 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 133 | 0.090 |
Why?
|
| Behavior, Addictive | 1 | 2010 | 31 | 0.090 |
Why?
|
| Checklist | 1 | 2010 | 35 | 0.090 |
Why?
|
| Diet | 1 | 2012 | 356 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2019 | 35 | 0.090 |
Why?
|
| Epidural Space | 1 | 2009 | 7 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 496 | 0.080 |
Why?
|
| Steroids | 1 | 2009 | 36 | 0.080 |
Why?
|
| HIV Infections | 1 | 2013 | 372 | 0.080 |
Why?
|
| Regression Analysis | 3 | 2013 | 275 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2018 | 85 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 1225 | 0.080 |
Why?
|
| Neck Pain | 1 | 2007 | 6 | 0.080 |
Why?
|
| Radiculopathy | 1 | 2007 | 5 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2008 | 164 | 0.070 |
Why?
|
| Sex Characteristics | 1 | 2008 | 167 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 50 | 0.070 |
Why?
|
| Hindlimb | 3 | 2007 | 57 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 105 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 174 | 0.070 |
Why?
|
| Forecasting | 1 | 2007 | 133 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 105 | 0.070 |
Why?
|
| Nortriptyline | 1 | 2006 | 2 | 0.070 |
Why?
|
| Carbamazepine | 1 | 2006 | 4 | 0.070 |
Why?
|
| Thoracotomy | 1 | 2006 | 22 | 0.070 |
Why?
|
| Reaction Time | 2 | 2007 | 121 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 643 | 0.070 |
Why?
|
| Fluoroscopy | 1 | 2006 | 39 | 0.070 |
Why?
|
| Mastectomy | 1 | 2006 | 60 | 0.070 |
Why?
|
| Anticonvulsants | 1 | 2006 | 63 | 0.070 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2003 | 27 | 0.070 |
Why?
|
| Prevalence | 1 | 2008 | 910 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 984 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 75 | 0.060 |
Why?
|
| Calcium | 2 | 2002 | 302 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2016 | 861 | 0.060 |
Why?
|
| Medicare | 1 | 2004 | 189 | 0.060 |
Why?
|
| Receptors, GABA | 1 | 2003 | 6 | 0.060 |
Why?
|
| Serotonin Antagonists | 1 | 2003 | 5 | 0.060 |
Why?
|
| GABA Antagonists | 1 | 2003 | 12 | 0.060 |
Why?
|
| Receptors, Serotonin | 1 | 2003 | 6 | 0.060 |
Why?
|
| Narcotics | 1 | 2003 | 18 | 0.050 |
Why?
|
| Quality of Life | 1 | 2008 | 833 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2003 | 81 | 0.050 |
Why?
|
| Exercise Test | 2 | 2013 | 194 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 14 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2002 | 56 | 0.050 |
Why?
|
| Research Subjects | 1 | 2022 | 28 | 0.050 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2001 | 5 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 68 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1430 | 0.050 |
Why?
|
| Chemokines | 1 | 2001 | 35 | 0.050 |
Why?
|
| Benzeneacetamides | 1 | 2001 | 3 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2001 | 13 | 0.050 |
Why?
|
| Somatostatin | 1 | 2001 | 10 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 727 | 0.050 |
Why?
|
| Naltrexone | 1 | 2001 | 38 | 0.050 |
Why?
|
| Indiana | 1 | 2020 | 4 | 0.050 |
Why?
|
| Peptides | 1 | 2001 | 118 | 0.050 |
Why?
|
| Skin Temperature | 1 | 2000 | 15 | 0.050 |
Why?
|
| Age Factors | 2 | 2013 | 1120 | 0.040 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 1999 | 32 | 0.040 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 1 | 1999 | 5 | 0.040 |
Why?
|
| Child | 2 | 2020 | 2233 | 0.040 |
Why?
|
| Norepinephrine | 1 | 1999 | 74 | 0.040 |
Why?
|
| Rest | 1 | 2019 | 50 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2013 | 1701 | 0.040 |
Why?
|
| Neural Pathways | 1 | 2019 | 97 | 0.040 |
Why?
|
| Logistic Models | 2 | 2015 | 729 | 0.040 |
Why?
|
| Brain Mapping | 1 | 2019 | 182 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2012 | 489 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2020 | 144 | 0.040 |
Why?
|
| Nerve Net | 1 | 2019 | 116 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2001 | 423 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2018 | 136 | 0.040 |
Why?
|
| Syndrome | 1 | 2017 | 66 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2016 | 2046 | 0.040 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2017 | 4 | 0.040 |
Why?
|
| Decision Making | 1 | 2018 | 182 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2016 | 95 | 0.030 |
Why?
|
| Decision Trees | 1 | 2015 | 23 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 214 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 149 | 0.030 |
Why?
|
| Sports | 1 | 2015 | 33 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1389 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 299 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 169 | 0.030 |
Why?
|
| Self Concept | 1 | 2013 | 42 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2013 | 55 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2008 | 2124 | 0.030 |
Why?
|
| African Americans | 1 | 2019 | 1375 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 242 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2010 | 14 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 59 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 864 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2010 | 114 | 0.020 |
Why?
|
| Injections, Epidural | 1 | 2009 | 9 | 0.020 |
Why?
|
| Lumbosacral Region | 1 | 2009 | 12 | 0.020 |
Why?
|
| Freund's Adjuvant | 1 | 2007 | 2 | 0.020 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2007 | 24 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2007 | 98 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2007 | 40 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 68 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 355 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2007 | 507 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2004 | 24 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2004 | 40 | 0.020 |
Why?
|
| Pneumonia | 1 | 2004 | 62 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2004 | 448 | 0.010 |
Why?
|
| Peripheral Nerves | 1 | 2004 | 59 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2004 | 115 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 638 | 0.010 |
Why?
|
| Prognosis | 1 | 2007 | 1372 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 2 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2001 | 11 | 0.010 |
Why?
|
| Receptors, CCR4 | 1 | 2001 | 3 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2001 | 9 | 0.010 |
Why?
|
| Bradykinin | 1 | 2001 | 18 | 0.010 |
Why?
|
| Substance P | 1 | 2001 | 22 | 0.010 |
Why?
|
| Capsaicin | 1 | 2001 | 30 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2001 | 53 | 0.010 |
Why?
|
| Tail | 1 | 2001 | 6 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2001 | 45 | 0.010 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2001 | 33 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2001 | 74 | 0.010 |
Why?
|
| Neurons, Afferent | 1 | 2001 | 54 | 0.010 |
Why?
|
| Yohimbine | 1 | 1999 | 4 | 0.010 |
Why?
|
| Dexmedetomidine | 1 | 1999 | 8 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1999 | 41 | 0.010 |
Why?
|
| Anesthesia, Spinal | 1 | 1999 | 21 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2001 | 523 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2001 | 803 | 0.010 |
Why?
|